Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

Background: Primary resistance to immunotherapy can be observed in approximately 40–65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of the patients receive a second-line therapy, and the clinical benefit is small. Patients and methods: Stage IV melanoma pa...

Full description

Bibliographic Details
Main Authors: Teresa Amaral, Olivia Seeber, Edgar Mersi, Stephanie Sanchez, Ioannis Thomas, Andreas Meiwes, Andrea Forschner, Ulrike Leiter, Thomas Eigentler, Ulrike Keim, Claus Garbe
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
metastatic melanoma
primary resistance
checkpoint-inhibitors
combined immunotherapy
pseudoprogression
Online Access:https://www.mdpi.com/2072-6694/12/4/1027

Internet

https://www.mdpi.com/2072-6694/12/4/1027

Similar Items